Kadi-Liis Veiman

TL;DR: This work introduces a novel method for in vivo delivery of plasmid DNA (pDNA) and efficient tumor-specific gene induction using intravenous (i.v) administration route and shows that this delivery vector effectively forms nanoparticles, where the condensed CPP and pDNA are shielded by the PEG, in an MMP-reversible manner.

TL;DR: PepFect14 (PF14) peptide, previously used for the transport of shorter oligonucleotides, is demonstrated to be suited also for the delivery of pDNA, and is shown that PF14 forms stable nanoparticles with pDNA with a negative surface charge and size of around 130-170 nm.

TL;DR: NF55 mediates DNA delivery in vivo with gene induction efficiency that is comparable to commercial transfection reagents and a solid formulation of NF55/DNA displayed an excellent stability profile without additives or special storage conditions make NF55 an excellent vector for the delivery of DNA in vivo.

TL;DR: An optimized formulation of PF14/pDNA nanocomplexes is developed, which allows removal of the side-effects without compromising the bioefficacy in vivo and shows that with an optimal combination of overall charge and hydrophobicity in the peptide backbone, in vivo gene delivery can be augmented.

TL;DR: The results suggest that activatable cell‐penetrating peptide PF144 is a promising nonviral plasmid DNA delivery vector for cancer treatment and the addition of αvβ3 integrin targeting did not further improve the tumor sensitive CPPs.